#SEKISUI DIAGNOSTICS DOWNLOAD#

Testing patients provides valuable information to the clinician that can enable them to rule out other illnesses, help determine treatment and reduces the risk of prescribing unnecessary antivirals or antibiotics. 'Accurate diagnosis of influenza is critical to minimize transmission of infection and we are proud to be able to provide sensitive and specific tools to healthcare professionals.'

We remain committed to providing innovative, high quality testing options so they can make the right choice for their practices and patients,' saidВ Robert Schruender, president /CEO of Sekisui Diagnostics. We take great pride in listening to our customers and we understand they have different needs during flu season. The launch of the Acucy Influenza A&B Test makes us the first and only company to provide the three most commonly used flu testing methods in a CLIA Waived format. Before joining the organisation in Kent, he. He has broad experience in Operations and site management in API manufacture and diagnostics. The Sekisui Diagnostics, LLC management team includes Bob Schruender (President and Chief Executive Officer), William Faranda (Vice President, Strategy and Business Development), and Alan Bauer (Vice President - Global Finance). Will Stockburn joined the Sekisui Diagnostics organisation in 2007 and has over 30 years of experience in the pharmaceutical, fine chemical and diagnostics industries, including over 20 years with Genzyme. The SHBG Testosterone Calculator application is designed to assist clinicians in accurately determining circulating bioactive testosterone levels. Get Sekisui Diagnostics for iOS latest version.

#SEKISUI DIAGNOSTICS DOWNLOAD#

'This is a very exciting time for Sekisui Diagnostics. Sekisui Diagnostics, LLC employs 200 employees. Download Sekisui Diagnostics App 1.0 for iPhone free online at AppPure. Sekisui Diagnostics now offers options to address the varying needs of the market to help improve patient outcomes, maximize clinical efficiencies, and reduce operational budgets. The addition of the AcucyВ Influenza A&B test expands Sekisui Diagnostics flu portfolio to include all three commonly used modalities in the CLIA Waived environment: OSOM Ultra Flu A&B Test (manual read lateral flow), Acucy Influenza A&B Test (point-of-care reader) and the SilarisВ Influenza A&B Test (molecular point-of-care). Utilizing the Acucy Reader in either the point-of-care or laboratory setting provides workflow flexibility with Read Now and Walk Away features. The combination of the Influenza A&B Test and the Reader provides clinicians with standardized and definitive result interpretation. The Acucy Influenza A&B Test is intended for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. Food and Drug Administration (FDA), as well as, CLIA Waiver (Clinical Laboratory Improvement Amendments) for use on the Acucy Reader. As a sister company to Sekisui Medical in Japan, we are globally positioned to meet your diagnostics needs.Sekisui DiagnosticsвЂ™ Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the U.S.

With more than 450 employees spread across 6 sites in four countries, we are a worldwide company with R&D and manufacturing on three continents. Product lines include clinical chemistry and coagulation systems and reagents, point-of-care molecular, rapid tests and immunoassay system as well as enzymes and.

Headquartered in Lexington, MA, our history of innovation includes the first homogeneous test for LDL and the first plastic vacuum blood collection tube. SEKISUI Diagnostics is committed to providing innovative medical diagnostics to physicians and laboratories, supplying billions of tests each year to the global healthcare market.

Point of care rapid tests and immunoassay system Sekisui Diagnostics is a diverse company with broad product lines, a global sales and distribution network, extensive product development capabilities.

Clinical chemistry systems and reagents.

We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. SEKISUI Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years.

Sekisui diagnostics